Olipudase alfa
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acid Sphingomyelinase Deficiency (ASMD)
Conditions
Acid Sphingomyelinase Deficiency (ASMD)
Trial Timeline
Jun 10, 2022 → Dec 31, 2024
NCT ID
NCT05359276About Olipudase alfa
Olipudase alfa is a pre-clinical stage product being developed by Sanofi for Acid Sphingomyelinase Deficiency (ASMD). The current trial status is completed. This product is registered under clinical trial identifier NCT05359276. Target conditions include Acid Sphingomyelinase Deficiency (ASMD).
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06192576 | Pre-clinical | Recruiting |
| NCT05359276 | Pre-clinical | Completed |
| NCT06949358 | Phase 2 | Completed |
| NCT02292654 | Phase 1/2 | Completed |
Competing Products
20 competing products in Acid Sphingomyelinase Deficiency (ASMD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Low Dose REN001 + High Dose REN001 | OnKure Therapeutics | Phase 1 | 25 |
| ONO-8539 | Ono Pharmaceutical | Phase 1 | 33 |
| LJN452 + Placebo to LJN452 | Novartis | Phase 2 | 52 |
| Insulin (Aspart Insulin [Novolog], Regular Insulin) | Novo Nordisk | Pre-clinical | 22 |
| Pantoprazole | Pfizer | Approved | 84 |
| Recombinant human acid sphingomyelinase | Sanofi | Phase 1 | 32 |
| insulin glargine+ glulisine + NPH + Regular insulin | Sanofi | Approved | 84 |
| Ataluren | Sanofi | Phase 2 | 51 |
| rhASM + rhASM + rhASM + rhASM + rhASM | Sanofi | Phase 1 | 32 |
| Omeprazole/sodium bicarbonate + omeprazole magnesium + sodium bicarbonate | Bayer | Phase 3 | 74 |
| Omeprazole/sodium bicarbonate + omeprazole magnesium (20 mg equivalent) | Bayer | Phase 3 | 74 |
| Zegerid + Prilosec OTC™ Tablets | Bayer | Phase 3 | 74 |
| A3384 | Ipsen | Phase 2 | 49 |
| Clinolipid + Intralipid | Baxter | Approved | 82 |
| Clinolipid + Intralipid | Baxter | Approved | 82 |
| Carglumic Acid | Recordati | Pre-clinical | 20 |
| Cholic acid | Mirum Pharmaceuticals | Phase 3 | 74 |
| AAV2-hAADC | PTC Therapeutics | Phase 2 | 49 |
| gene therapy | PTC Therapeutics | Phase 1/2 | 38 |
| Cholbam | Mirum Pharmaceuticals | Pre-clinical | 20 |